Skip to content
lifestyle.jardal-paintball.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Legend Biotech USA Inc.
Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results
July 28, 2026
Legend Biotech Announces CEO Transition
July 27, 2026
Legend Biotech Corporation Announces Pricing of Public Offering
June 17, 2026
Legend Biotech Corporation Announces Proposed Public Offering
June 17, 2026
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
June 15, 2026
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
June 14, 2026
Legend Biotech Announces Presentations at ASCO 2026
May 21, 2026
Legend Biotech Reports First Quarter 2026 Results and Recent Highlights
May 12, 2026
Legend Biotech Expands Scientific Advisory Expertise to Inform Future Growth
May 4, 2026
Legend Biotech to Host Investor Conference Call on First Quarter 2026 Results
April 28, 2026
1
2
Next Page
→